BELLEVILLE, ON, March 27 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC),
a research-based, technology-driven Canadian biopharmaceutical company, today
announced that the Company has exercised its right under the agreement to
repay US$1.75 million of its secured revolving credit facility with Valens
U.S. (formerly Laurus Master Funds) in common shares.
